Where would you like to sign in?

BIOLASE Receives European Patent for Its Laser Pulse Technology

IRVINE, CA -- (MARKET WIRE) -- October 25, 2006 -- BIOLASE Technology, Inc. (NASDAQ: BLTI), a
medical technology company that develops, manufactures and markets lasers
and related products focused on technologies for improved applications and
procedures in dentistry and medicine, announced today it has been granted a
new European patent related to proprietary laser and pulse technology with
claims covering key laser pulse structures, as well as soft and hard tissue
applications.

President and CEO Jeffrey W. Jones said that this patent represents a
significant expansion in BIOLASE's European patent position. "BIOLASE
already has more than 100 patents for laser technology and its
applications, with the latest being reported as recently as last month,"
Jones added. "This new European patent contains broad claims that cover
unique and important laser pulse characteristics in our substantial laser
technology portfolio. Not only does this technology drive systems such as
our Waterlase® Dental Laser System, it also covers additional
applications beyond dentistry and medicine and expands our intellectual
property position in the European community. We remain committed to
innovation that furthers our core technology and protects our market
leading position in the field of laser dentistry."

The patent, No. 1 016 328 B1, was granted in Germany, Great Britain,
France, Spain and Italy and contains 49 claims of which two are
independent. The claims provide protection for methods and the apparatus
related to pulse technologies and the circuitry that comprise lasers which
operate in conjunction with fluid, gas or water, to impart disrupted forces
to materials including tissues. The patent also covers key laser pulse
structures responsible for fast and effective methods for using the laser
on teeth, bone, cartilage and soft tissue. Some of these pulse structures
are incorporated in BIOLASE products employing the Company's Er,Cr: YSGG
technology. The combination of specialized laser pulses, laser wavelength
and fluid output technology is one of the critical driving factors behind
the Company's proprietary Waterlase technology.

About BIOLASE Technology, Inc.

BIOLASE Technology, Inc. (http://www.biolase.com) is a medical technology
company that develops, manufactures and markets lasers and related products
focused on technologies for improved applications and procedures in
dentistry and medicine. The Company's products incorporate patented and
patent pending technologies focused on reducing pain and improving clinical
results. Its primary product, the Waterlase® system, is one of the best
selling dental laser systems. The Waterlase system uses a patented
combination of water and laser to precisely cut hard tissue, such as bone
and teeth, and soft tissue, such as gums, with minimal or no damage to
surrounding tissue. The Company also offers the LaserSmile™ system,
which uses a laser to perform soft tissue and cosmetic procedures,
including teeth whitening. The Company is also developing a laser for use
in the field of ophthalmology.

This press release may contain forward-looking statements within the
meaning of safe harbor provided by the Securities Reform Act of 1995 that
are based on the current expectations and estimates by our management.
These forward-looking statements can be identified through the use of words
such as "anticipates," "expects," "intends," "plans," "believes," "seeks,"
"estimates," "may," "will," and variations of these words or similar
expressions. Forward-looking statements are based on management's current,
preliminary expectations and are subject to risks, uncertainties and other
factors which may cause the Company's actual results to differ materially
from the statements contained herein, and are described in the company's
reports it files with the Securities and Exchange Commission, including its
annual and quarterly reports. No undue reliance should be placed on
forward-looking statements. Such information is subject to change, and we
undertake no obligation to update such statements.